Advanced search
Publication Cover
Modern Rheumatology Volume 30, 2020 - Issue 1
Journal homepage
288
Views
20
CrossRef citations to date
0
Altmetric
Original Articles: Connective Tissue Diseases and Related Disorders

Safety and tolerability of sifalimumab, an anti-interferon-α monoclonal antibody, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study

Tsutomu TakeuchiDivision of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan; Correspondence[email protected]
,
Yoshiya TanakaFirst Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan;
,
Ryutaro MatsumuraDepartment of Allergy, National Hospital Organization, Chiba-East Hospital, Chiba, Japan;
,
Kazuyoshi SaitoFirst Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan;
,
Mitsuhiro YoshimuraDepartment of Internal Medicine, National Hospital Organization, Kanazawa Medical Center, Ishikawa, Japan;
,
Koichi AmanoDepartment of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan;
,
Tatsuya AtsumiDepartment of Rheumatology, Endocrinology and Nephrology, Hokkaido University Hospital, Hokkaido, Japan;
,
Eiichi SuematsuDepartment of Internal Medicine and Rheumatology, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan;
,
Nobuya HayashiDepartment of Research and Development, AstraZeneca K.K, Osaka, Japan;
,
Liangwei WangAstraZeneca, Gaithersburg, MD, USA
&
Raj TummalaAstraZeneca, Gaithersburg, MD, USA
 show all
Pages 93-100 | Received 17 Oct 2018, Accepted 08 Feb 2019, Published online: 25 Mar 2019

Citations (20)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Jacqueline L. Paredes & Timothy B. Niewold. (2020) Type I interferon antagonists in clinical development for lupus. Expert Opinion on Investigational Drugs 29:9, pages 1025-1041.
Read now

Articles from other publishers (19)

Márk Juha, Adél Molnár, Zoltán Jakus & Nóra Ledó. (2023) NETosis: an emerging therapeutic target in renal diseases. Frontiers in Immunology 14.
Crossref
Yoshiya Tanaka, Masaki Kusuda & Yoshiyuki Yamaguchi. (2023) Interferons and systemic lupus erythematosus: Pathogenesis, clinical features, and treatments in interferon-driven disease. Modern Rheumatology 33:5, pages 857-867.
Crossref
Njundu Jatta, Johnson Stanslas, Audrey Chee Hui Yong, Wen Chung Ho, Wan Syazween Lyana Wan Ahmad Kammal, Eng Wee Chua & Kang Nien How. (2023) Whole blood hydroxychloroquine: Does genetic polymorphism of cytochrome P450 enzymes have a role?. Clinical and Experimental Medicine.
Crossref
Yibing Han, Lingwei Liu, Bo Zang, Ruiwen Liang, Xinyue Zhao & Bin Liu. (2023) Advances in natural products and antibody drugs for SLE: new therapeutic ideas. Frontiers in Pharmacology 14.
Crossref
Giovanni Battista Dell’Isola, Gianluca Dini, Kaleb Logan Culpepper, Katherin Elizabeth Portwood, Pietro Ferrara, Giuseppe Di Cara, Alberto Verrotti & Mauro Lodolo. (2023) Clinical spectrum and currently available treatment of type I interferonopathy Aicardi–Goutières syndrome. World Journal of Pediatrics 19:7, pages 635-643.
Crossref
Sebastian Bruera, Thandiwe Chavula, Riya Madan & Sandeep K. Agarwal. (2023) Targeting type I interferons in systemic lupus erythematous. Frontiers in Pharmacology 13.
Crossref
Smitha Hosahalli Vasanna & Jignesh Dalal. (2023) Traffic jam within lymphocytes: A clinician’s perspective. Frontiers in Immunology 13.
Crossref
Enrico Celestino Nista, Sara Sofia De Lucia, Vittoria Manilla, Tommaso Schepis, Antonio Pellegrino, Veronica Ojetti, Giulia Pignataro, Lorenzo Zileri dal Verme, Francesco Franceschi, Antonio Gasbarrini & Marcello Candelli. (2022) Autoimmune Pancreatitis: From Pathogenesis to Treatment. International Journal of Molecular Sciences 23:20, pages 12667.
Crossref
Sophia Weidler & Min Ae Lee-Kirsch. (2022) Typ-1-Interferonopathien. Arthritis und Rheuma 42:04, pages 236-240.
Crossref
Panagiotis Petrou. (2022) A Systematic Review of the Economic Evaluations of Belimumab in Systemic Lupus Erythematosus. Value in Health Regional Issues 27, pages 32-40.
Crossref
Charalampos Skarlis & Clio P. Mavragani. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology 479 491 .
Michel W. P. Tsang-A-Sjoe & Irene E. M. Bultink. (2021) New developments in systemic lupus erythematosus. Rheumatology 60:Supplement_6, pages vi21-vi28.
Crossref
Giulia Di Donato, Debora Mariarita d’Angelo, Luciana Breda & Francesco Chiarelli. (2021) Monogenic Autoinflammatory Diseases: State of the Art and Future Perspectives. International Journal of Molecular Sciences 22:12, pages 6360.
Crossref
Debora M. d'Angelo, Paola Di Filippo, Luciana Breda & Francesco Chiarelli. (2021) Type I Interferonopathies in Children: An Overview. Frontiers in Pediatrics 9.
Crossref
Antonios G.A. Kolios, Nobuya Yoshida & George C. Tsokos. (2021) New therapeutic approaches in systemic lupus erythematosus. Current Opinion in Rheumatology 33:2, pages 181-189.
Crossref
Sung-Hoon Park. (2021) Biologic therapies for the treatment of systemic lupus erythematosus. Journal of the Korean Medical Association 64:2, pages 109-115.
Crossref
Shereen Oon. 2021. Pathogenesis of Systemic Lupus Erythematosus. Pathogenesis of Systemic Lupus Erythematosus 67 95 .
Bingyi Yang, Ming Zhao, Haijing Wu & Qianjin Lu. (2020) A Comprehensive Review of Biological Agents for Lupus: Beyond Single Target. Frontiers in Immunology 11.
Crossref
Erkan Demirkaya, Sezgin Sahin, Micol Romano, Qing Zhou & Ivona Aksentijevich. (2020) New Horizons in the Genetic Etiology of Systemic Lupus Erythematosus and Lupus-Like Disease: Monogenic Lupus and Beyond. Journal of Clinical Medicine 9:3, pages 712.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.